Author:
Schettini Francesco,De Bonis Maria Valeria,Strina Carla,Milani Manuela,Ziglioli Nicoletta,Aguggini Sergio,Ciliberto Ignazio,Azzini Carlo,Barbieri Giuseppina,Cervoni Valeria,Cappelletti Maria Rosa,Ferrero Giuseppina,Ungari Marco,Locci Mariavittoria,Paris Ida,Scambia Giovanni,Ruocco Gianpaolo,Generali Daniele
Abstract
AbstractMathematical models based on partial differential equations (PDEs) can be exploited to handle clinical data with space/time dimensions, e.g. tumor growth challenged by neoadjuvant therapy. A model based on simplified assessment of tumor malignancy and pharmacodynamics efficiency was exercised to discover new metrics of patient prognosis in the OLTRE trial. We tested in a 17-patients cohort affected by early-stage triple negative breast cancer (TNBC) treated with 3 weeks of olaparib, the capability of a PDEs-based reactive–diffusive model of tumor growth to efficiently predict the response to olaparib in terms of SUVmax detected at 18FDG-PET/CT scan, by using specific terms to characterize tumor diffusion and proliferation. Computations were performed with COMSOL Multiphysics. Driving parameters governing the mathematical model were selected with Pearson's correlations. Discrepancies between actual and computed SUVmax values were assessed with Student’s t test and Wilcoxon rank sum test. The correlation between post-olaparib true and computed SUVmax was assessed with Pearson’s r and Spearman’s rho. After defining the proper mathematical assumptions, the nominal drug efficiency (εPD) and tumor malignancy (rc) were computationally evaluated. The former parameter reflected the activity of olaparib on the tumor, while the latter represented the growth rate of metabolic activity as detected by SUVmax. εPD was found to be directly dependent on basal tumor-infiltrating lymphocytes (TILs) and Ki67% and was detectable through proper linear regression functions according to TILs values, while rc was represented by the baseline Ki67-to-TILs ratio. Predicted post-olaparib SUV*max did not significantly differ from original post-olaparib SUVmax in the overall, gBRCA-mutant and gBRCA-wild-type subpopulations (p > 0.05 in all cases), showing strong positive correlation (r = 0.9 and rho = 0.9, p < 0.0001 both). A model of simplified tumor dynamics was exercised to effectively produce an upfront prediction of efficacy of 3-week neoadjuvant olaparib in terms of SUVmax. Prospective evaluation in independent cohorts and correlation of these outcomes with more recognized efficacy endpoints is now warranted for model confirmation and tailoring of escalated/de-escalated therapeutic strategies for early-TNBC patients.
Funder
European Society for Medical Oncology
Fundación BBVA
AstraZeneca
Mednote
Publisher
Springer Science and Business Media LLC
Reference51 articles.
1. SEER statistics for breast cancer [Internet]. [cited 2021 Jul 25]. Available from: Available at https://seer.cancer.gov
2. Wojtyla, C., Bertuccio, P., Wojtyla, A. & La Vecchia, C. European trends in breast cancer mortality, 1980–2017 and predictions to 2025. Eur. J. Cancer 152, 4–17 (2021).
3. Pérez-García, J., Gebhart, G., Ruiz Borrego, M., Stradella, A., Bermejo, B. P. S. et al. Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): A multicentre, randomised, open-label, non-comparative, phase 2 trial. Lancet Oncol. 22 (2021).
4. Blumen, H., Fitch, K. & Polkus, V. Comparison of treatment costs for breast cancer, by tumor stage and type of service. Am. Health Drug Benefits 9, 23–32 (2016).
5. Varsanik, M. A. & Shubeck, S. P. De-escalating breast cancer therapy. Surg. Clin. N. Am. 103, 83–92 (2023).